Recombinant major histocompatibility complex (MHC) class II molecules were expressed with extracdlular polypeptide domains reorganized to form heavy (H) and light (L) chains (oq-/31-/32 and (x2) analogous to class I. Accurate protein folding and dimerization is demonstrated by the ability of this 3 + 1-DR1 construct to bind class II-restricted peptides and stimulate CD4 + T ceils. Cell surface expression of a functional class II molecule consisting of H and L chains supports the validity of current class II models and affirms the evolutionary relatedness of class I/II. MHC functions that differ between class I/II may be influenced by domain configuration, and the use of domain-shifted constructs will allow examination of this possibility.
T
he class I and II molecules encoded in the MHC function to bind short peptide fragments and display them at the call surface where they can be recognized by CD8 § and CD4 + T cells, respectively. Important differences exist in the intracdlular trafficking of these molecules and their prindpal sites of peptide acquisition (1) . Class I molecules bind endogenously synthesized peptides of 8-10 amino acids in length within the endoplasmic reticulum (2) . Conversely, class II molecules preferenthlly bind exogenous peptides, which are longer and more variable in length (13-20 residues) , in an endosomal compartment (3) . The ability of class II molecules to bind longer peptides has suggested the possibility that their peptide binding groove, in contrast to class I, has at least one "open" end that accommodates heterogeneous peptides by allowing residues to extend away from the class II molecule (3) .
Both class I and II MHC molecules are heterodimeric glycoproteins containing four extracdlular domains. Each contains two membrane proximal domains that bear sequence homology to the Ig superfamily, and two membrane distal domains that together form the peptide binding and T ceil recognition sites. These molecules differ, however, in the distribution of protein domains among the two polypeptide chains. Chss I mol~ules consist of a three domain, membraneassociated H chain (c~l-ot2-ot3) and a single domain L chain which is not membrane assodated (13z-microglobulin). In contrast, class II molecules consist ofc~ and/3 chains of similar size, each containing two protein domains. Class II structure has been modeled (4) on the crystallographic structure of class I (5, 6), and preliminary reports suggest that the overall conformations of these molecules are indeed similar (7) . However, it is unknown what structural or functional differences result when the peptide binding site is generated by an intermolecular dimer (as in class II) rather than an intramolecular dimer (as in class I).
Using recombinant techniques, we tested the ability of class II molecules to assemble in a configuration with polypeptide domains reorganized into H and L chains analogous to class I. This "3 + 1-DILl" molecule is expressed on the ceil membrane in a conformation recognized by dass II-specific mAbs. Importantly, this construct also functions in antigen presentation upon pulsing with synthetic peptide antigen. Cell surface expression of a functional 3 + 1-DR1 molecule provides experimental support for the class II binding site model, and allows examination of functional properties of dass II molecules which may be conferred by domain configuration independent of linear amino acid sequence.
Materials and Methods
cDNA Clones. Full-length HLA-DR ce and/3 chain cDNA clones in the pCD expression vector were used in these studies. The DR.A cDNA, encoding the DK ce chain, was isolated as described (8 Splicing of cDNA Encoding ot and/3 Chains. The PCtL method of splicing by overlap extension (10) was used to generate cDNAs encoding HLA-DR1 chains analogous to H and L chains of class I molecules, cDNA encoding the c~1 domain was ligated to the /3 chain cDNA, positioned between leader sequence and/3t domain cDNA, yidding a cDNA encoding an oh-/31-/32 chain (see Fig. 2 ). Within the c~1-/31-/32 chain, amino acid 84 of the c~1 domain is attached directly to amino acid 1 of the /31 domain, without insertion of"spacer" residues. A transmembrane-associated c~z construct was generated by splicing out the c~1 domain, and attaching leader sequence cDNA directly to the first amino acid of the a2 domain (amino acid 85 within the c~ chain), cDNA encoding a soluble c~2 chain was generated by incorporation of a stop codon at the connecting peptide/transmembrane segment by sitedirected mutagenesis (11) . All cDNA constructs were ligated into the original pCD vectors, and the entire DNA insert was sequenced to confirm the desired product.
Abs. The following HLA class II-specific mAb were used in these studies: SG157 (obtained from Sanna Goyert, North Shore University Hospital, Manhasset, NY) (12); HU-26 (from Akemi Wakisaka, Hokkaido University School of Medicine, Sapporo, Japan) (13); LB3.1 (from Joan Gorga, Harvard University, Cambridge, MA) (14) ; and L243 (ATCC) (15) .
Transfection. Cells of the DAP.3 subclone of class II-negative murine L cell fibroblasts were transfected using the calcium phosphate coprecipitation method as described (16) . Transfections included 1 #g of the pSV2-neo plasmid and 20 #g each of plasmids containing DRo~t-fll-fl2 chain and DRo~2 or DKo~2-soluble chain cDNA. Control transfections, each including 1 #g pSV2-neo plasmid, included the following: 20/zg each of plasmids containing wild-type DR c~ and fl chains; 40 #g of cr plasmids; 40 #g of c~2-containing plasmid. G418-resistant transfectant clones with stable surface expression of molecules recognized by SG157 were isolated by flow cytometric sorting as described (16) .
T Cell Clones. HLA-DKl-restricted clone HA-l, specific for influenza A hemagglutinin H3 residues 307-319, was derived by in vitro stimulation as described (17) 
T CelIProliferation Assays. L cell transfectants expressing human
MHC molecules were irradiated (3,000 tad) and seeded at 2 x 104.cells/well in 96-well plates. Wells were pulsed overnight with peptide at the indicated concentrations, and washed twice with PBS before the addition of 5 x 104 T cells/well. After 48 h culture, wells were pulsed for 14-16 h with 1.0 #Ci 3H[TdR], harvested onto glass filters, and assessed by liquid scintillation counting. Results are expressed as the mean counts per minute of triplicate wells. Individual replicates were within 15% of the mean.
Metabolic Cell Labeling. L cell transfectants were plated in 150 cm 2 tissue culture flasks at 107 cells/flask and incubated overnight. Flasks were washed twice with sterile PBS before the addition of leucine-free Eagle's MEM containing 10% dialysed FCS, 1 mM glutamine, penicillin, streptomycin, and 0.3 pCi/ml 3H-hucine (152 Ci/mmol, Amersham Corp., Arlington Heights, IL). Cells were incubated for 6 h at 37~ rinsed twice with PBS, and detached using a rubber policeman into 5 ml PBS. Cells were centrifuged and resuspended in lysis buffer (150 mM NaC1, 50 mM Tris, pH 7.4, 1% NP-40, 0,02% NAN3, 50 /zg/ml PMSF, 50 /~g/ml leupeptin, 50/~g/ml Pepstatin A) at 3 x 107 cell equivalents/ml. Lysates were incubated at 4~ for 30 min, centrifuged at 14,000 rpm at 4~ for 30 min, and supernatants collected and stored at -
20~
Immunoprecipitations and Gel Electrophoresis. I ml cell lysate was precleared by incubation with 300 ~1 Zysorbin G (Zymed Laboratories, Inc., South San Francisco, CA) and 5 Izg MOPC 195 (Cappel Laboratories, West Chester, PA) overnight at 40C. The Zysorbin G was pelleted and the supernatant was incubated for 6 h at 4~ with 25 #1 protein G-scpharose (Pharmacia, Piscataway, NJ) prearmed by incubation with mAb L243. The protein G-Sepharosc was washed twice with TBS, twice with 0.5% Tween X-100 in TBS, then twice in TBS. After centrifugation, the protein G-Sepharose was resuspended in SDS-PAGE reducing sample buffer (0.0625 M Tris, 10% glycerol, 5% r-ME, 2.3% SDS, pH 6.8), boiled for 10 min, and vortexed before pelleting. Supernatants were analyzed on discontinuous SDS-polyacrylamide gels (5% stacking gel, 12.5% running gel). Gels were fixed for 30 min in 25% isopropanol/10% acetic acid, soaked for 30 minutes in Amplify (Amersham Corp.), dried, and exposed to film for 3-7 d at -70~
Results and Discussion
cDNAs encoding fuLl-length DP, ce and DR.lfl chains were spliced to encode chains analogous to the H and L chains of class I MHC molecules (Fig. 1) . cDNAs were designed Figure 1 . PCR. splicing of cDNAs encoding DR.loe and fl chains. AB and CD fragments were generated in independent PCR reactions, and the desired products were isolated from agarose gels. In a third PCR reaction, AB and CD fragments containing overlapping segments were annealed and extended to form AD fragments which incorporate unique resttiction enzyme sites. to encode covalent attachment of the oq domain COOHterminus to the BI domain NH2-terminus, based upon domain homologies with dass I molecules (patterns of conserved sequence and disulfide bonds) (4). This 3 + 1-DR1 molecule, shown diagrammatically in Fig. 2 , consists of a three domain c~1-~r~2 chain and single domain, membrane-bound cr chain. The membrane distal, NH2-terminal domains forming the sites for interaction with peptide and TCR are thus contributed by the same polypeptide chain, analogous to dass I. In addition, the 3 + 1-DR1 molecule no longer has the covalent association between oh and o~2 domains characteristic of class II molecules. After cloning of cDNAs into the pCD expression vector, cotransfection of class II-negative murine L cells, and G418 selection, surface expression of molecules recognized by the human class II-specific mAb SG157 was detected. Analysis of uncloned transfectants receiving o~2 and o~v~1-~2 chains demonstrated expression of the 3 + 1-DR1 molecule, whereas, transfection of vectors encoding either c~z or cr chains alone did not result in cell surface expression of molecules detected by SG157 (data not shown). Also, there was no detectable cell surface expression of a 3 + 1-DR1 molecule using cDNAs encoding the c~t-/~v,62 chain and a soluble o~2 chain construct (data not shown). These results may reflect a requirement for interactions between transmembrane segments of c~ and/3 chains in formation of the class II dimer as recently described (19) .
3+I-DRI
L cell clones with stable expression of the SG157 epitope were isolated by a single round of flow cytometric sorting and tested for recognition by additional mAbs recognizing HLA-DR1 (Fig. 3) . mAbs L243 and LB3.1 each recognized 3 + 1-DR1 transfectant clones comparably to conventional DILl transfectants that were selected for similar levels of SG157 expression. However, the epitope recognized by mAb HU26 was disrupted in the 3 + 1-DR1 transfectant relative to conventional DPd-expressing control transfectants. This HLA-DR epitope has previously been mapped to/3 chain position 4 (20) , and thus may be disrupted in the 3 + 1-DR1 molecule by the covalent attachment of the oL chain to the/3 chain NH2 terminus (Fig. 4) . However, the overall conformation of the 3 + 1-DR1 construct appears to be comparable to conventional DR1, as demonstrated with mAbs SG157, LB3.1, and L243.
Although the 3 + 1-DR1 H and L chains fold into a structure that reconstitutes certain mAb recognition sites, the ability of this heterodimer to bind peptide and serve as a functional TCR ligand is a more meaningful test of conformation. Therefore, 3 + 1-DRl-expressing L cell clones were used as APC in proliferation assays with antigen-specific, DRl-restricted T cell clones. Clones HA-1 and N3A9, specific for peptides
(COOH) derived from influenza hemagglutinin and M. leprae heat shock protein, proliferated comparably to peptide-pulsed transfectants expressing either conventional or 3 + 1-DR1 molecules (Fig. 5) . Therefore, the class I-like domain configuration did not impair the ability of the 3 + 1-DR1 molecule to bind peptide in a conformation allowing T cell stimulation. Class I molecules bind and present antigenic peptides that are shorter and more homogeneous in length compared to class II. Peptide truncation analog experiments as well as peptide elution studies with class I molecules indicate a strong preference for 8-10 residue peptides (21, 22) . Within the class I molecule, pockets of conserved MHC residues at each end of the binding groove interact closely with COOH-and NH2-terminal peptide residues to confer this length preference. Our results demonstrate that 13 and 14 residue peptides can bind to, and be presented by, the 3 + 1-DR1 construct. Thus, the covalent linkage between oq and ~1 domains does not disrupt the ability to bind peptides of this length, and the "open-endedness" of the class II binding site does not appear to depend upon the lack of covalent attachment between NHTterminal domains.
Metabolically labeled 3 + 1-DR1 molecules were immunoprecipitated and analyzed by SDS-PAGE. The results confirmed the expected molecular weights of the o~2 (21 kD) and o~v ~1-/32 (48 kD) chains (Fig. 6) , and excludes the possibility that L cell clones expressing murine class II molecules were selected. The ol2 chain, in contrast to 32-microglobulin, contains connecting peptide, transmembrane, and cytoplasmic segments, resulting in a correspondingly higher molecular weight.
Several pieces of evidence support the notion that the tertiary structures of class I and II molecules are highly homologous, including their overall domain composition, the presence of a single peptide binding site, patterns of conserved amino acids (4), the ability of certain T cells to recognize either class of MHC molecule (23) , and the results of a detailed mutational analysis of the murine class II o~ chain (24) . Indeed, preliminary reports of the HLA-DR1 structure suggest the overall validity of this model (7) . However, differences in domain configuration could translate into important differences in quaternary protein structure, flexibility, or function. The present data supports the concept that class II assumes a conformation similar to class I, by demonstrating that HLA-DR1 conformation is not dramatically altered upon reorganization of its linear amino acid sequence into H and L chains analogous to class I.
The different domain configurations of class I and II MHC molecules may have evolved because they provide distinct functional properties related to antigen presentation. Certain MHC functions may be permitted, or quantitatively altered, by domain configuration, including peptide selection, kinetics of peptide binding and release, chaperone protein interactions, recycling of surface-expressed molecules, and "retrograde" signaling via the MHC molecule to the APC. The expression of MHC molecules with identical linear sequence but differing domain configurations allows direct testing of the functional correlates of domain organization, independent of linear amino acid sequence. 
